AEON Biopharma, Inc DEFA14A, filed May 14, 2024

AEON Biopharma, Inc. (AEON)

DEFA14A 2024-05-14

View Original

Added on October 20, 2026

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

☑		Filed by the Registrant	☐	Filed by a Party other than the Registrant
Check the appropriate box:
☐	Preliminary Proxy Statement
☐	Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐	Definitive Proxy Statement
☑	Definitive Additional Materials
☐	Soliciting Material Under §240.14a-12


Payment of Filing Fee (Check all boxes that apply):

☒				No fee required.

☐				Fee paid previously with preliminary materials.

☐				Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


Delaware	85-3940478
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)


Title of Each Class	Trading symbol	Name of Exchange on which registered
Class A common stock, $0.0001 par value per share	AEON	NYSE American


Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒	Emerging growth company	☒


			Page

Part I

Item 1.	Business		2
Item 1A.	Risk Factors		32
Item 1B.	Unresolved Staff Comments		77
Item 1C.	Cybersecurity		77
Item 2.	Properties		79
Item 3.	Legal Proceedings		79
Item 4.	Mine Safety Disclosures		79

Part II

Item 5.	Market for Registrant’s Common equity, Related Stockholder Matters and Issuer Purchases of Equity Securities		79
Item 6.	Reserved		80
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		81
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk		102
Item 8.	Financial Statements and Supplementary Data		103
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure		148
Item 9A.	Controls and Procedures		148
Item 9B.	Other Information		149
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections		149

Part III

Item 10.	Directors, Executive Officers and Corporate Governance		150
Item 11.	Executive Compensation		150
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters		150
Item 13.	Certain Relationships and Related Transactions, and Director Independence		150
Item 14.	Principal Accounting Fees and Services		150

Part IV

Item 15.	Exhibits and Financial Statement Schedules		151
Item 16.	Form 10-K Summary		153

Exhibit Index		152

Signatures		154


	Year Ended
	December 31,
	2023				2022
		Predecessor January 1 to July 21		Successor July 22 to December 31		Predecessor January 1 to December 31
				(As restated)
Operating expenses:
Selling, general and administrative	$	9,841	$	9,949	$	13,675
Research and development		19,803		13,243		34,754
Acquired in-process research and development		—		348,000		—
Change in fair value of contingent consideration		—		(52,750)		—
Total operating costs and expenses		29,644		318,442		48,429
Loss from operations		(29,644)		(318,442)		(48,429)
Other (loss) income:
Change in fair value of convertible notes		(19,359)		—		(4,416)
Change in fair value of warrants		—		2,318		—
Change in fair value of embedded forward purchase agreements and derivative liabilities		(11,789)		(8,366)		—
Other income, net		114		536		289
Total other loss, net		(31,034)		(5,512)		(4,127)
Loss before taxes		(60,678)		(323,954)		(52,556)
Income taxes		—		—		—
Net loss and comprehensive loss	$	(60,678)	$	(323,954)	$	(52,556)
Basic and diluted net loss per share	$	(0.44)	$	(8.72)	$	(0.38)
Weighted average shares of common stock outstanding used to compute basic and diluted net loss per share		138,848,177		37,159,600		138,848,177


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2023				2022		2023				2022
		Predecessor July 1 to July 21		Successor July 22 to September 30		Predecessor July 1 to September 30		Predecessor January 1 to July 21		Successor July 22 to September 30		Predecessor January 1 to September 30
				(As restated)						(As restated)
Operating expenses:
Selling, general and administrative	$	1,055	$	5,265	$	2,436	$	9,841	$	5,265	$	8,171
Research and development		1,573		6,388		7,477		19,803		6,388		25,225
Acquired in-process research and development		—		348,000		—		—		348,000		—
Change in fair value of contingent consideration		—		(75,939)		—		—		(75,939)		—
Total operating costs and expenses		2,628		283,714		9,913		29,644		283,714		33,396
Loss from operations		(2,628)		(283,714)		(9,913)		(29,644)		(283,714)		(33,396)
Other (loss) income:
Change in fair value of convertible notes		(13,249)		—		(666)		(19,359)		—		15,261
Change in fair value of warrants		—		1,593		—		—		1,593		—
Change in fair value of embedded forward purchase agreements and derivative liabilities		(11,789)		(15,776)		—		(11,789)		(15,776)		—
Other income, net		5		186		141		114		186		142
Total other (loss) income, net		(25,033)		(13,997)		(525)		(31,034)		(13,997)		15,403
Loss before taxes		(27,661)		(297,711)		(10,438)		(60,678)		(297,711)		(17,993)
Income taxes		—		—		—		—		—		—
Loss and comprehensive loss	$	(27,661)	$	(297,711)	$	(10,438)	$	(60,678)	$	(297,711)	$	(17,993)
Basic and diluted net loss per share	$	(0.20)	$	(8.01)	$	(0.08)	$	(0.44)	$	(8.01)	$	(0.13)
Weighted average shares of common stock outstanding used to compute basic and diluted net loss per share		138,848,177		37,159,600		138,848,177		138,848,177		37,159,600		138,848,177



Report of Independent Registered Public Accounting Firm (PCAOB ID Number 185)		104

Report of Independent Registered Public Accounting Firm (PCAOB ID Number 42)		105

Consolidated Balance Sheets as of December 31, 2023 (Successor) and December 31, 2022 (Predecessor)		106

Consolidated Statements of Operations and Comprehensive Loss for the periods from January 1, 2023 to July 21, 2023 (Predecessor) and July 22, 2023 to December 31, 2023 (Successor) (As restated) and for the year ended December 31, 2022 (Predecessor)		107

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit for the periods from January 1, 2023 to July 21, 2023 (Predecessor) and July 22, 2023 to December 31, 2023 (Successor) (As restated) and for the year ended December 31, 2022 (Predecessor)		108

Consolidated Statements of Cash Flows for the periods from January 1, 2023 to July 21, 2023 (Predecessor) and July 22, 2023 to December 31, 2023 (Successor) (As restated) and for the year ended December 31, 2022 (Predecessor)		109

Notes to Consolidated Financial Statements		110


	Successor		Predecessor
	December 31,		December 31,
	2023		2022

ASSETS
Current assets:
Cash and cash equivalents	$	5,158	$	9,746
Prepaid expenses and other current assets		1,064		92
Total current assets		6,222		9,838
Property and equipment, net		332		431
Operating lease right-of-use asset		262		475
Other assets		29		34
Total assets	$	6,845	$	10,778
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable	$	3,388	$	7,805
Accrued clinical trials expenses		5,128		2,051
Accrued compensation		943		1,112
Other accrued expenses		3,590		740
Current portion of convertible notes at fair value, including related party amount of $0 and $38,834 at December 31, 2023 and December 31, 2022, respectively		—		70,866
Total current liabilities		13,049		82,574
Convertible notes at fair value, including related party amount of $0 and $23,132, at December 31, 2023 and December 31, 2022, respectively		—		60,426
Operating lease liability		—		242
Warrant liability		1,447		—
Contingent consideration liability		104,350		—
Embedded forward purchase agreements and derivative liabilities		41,043		—
Total liabilities		159,889		143,242
Commitments and contingencies
Convertible preferred stock issuable in series, $0.0001 par value; 44,666,035 shares authorized as of December 31, 2022; 21,257,708 shares issued and outstanding at December 31, 2022; liquidation preference of $141,920 at December 31, 2022		—		137,949
Stockholders’ Deficit:
AEON Biopharma, Inc. stockholders’ deficit:
Class A common stock, $0.0001 par value; 500,000,000 and 207,450,050 shares authorized, 37,159,600 and 138,848,177 shares issued and 37,159,600 and 138,825,356 shares outstanding at December 31, 2023 and December 31, 2022, respectively		4		14
Additional paid-in capital		381,264		187,348
Subscription receivables		(60,710)		—
Accumulated deficit		(473,602)		(474,839)
Treasury stock, at cost, 0 and 22,821 shares at December 31, 2023 and December 31, 2022, respectively		—		(23)
Total AEON Biopharma, Inc. stockholders’ deficit		(153,044)		(287,500)
Non-controlling interest		—		17,087
Total stockholders' deficit		(153,044)		(270,413)
Total liabilities, convertible preferred stock and stockholders' deficit	$	6,845	$	10,778


	Convertible						Additional											Non-	Total
	Preferred Stock			Common Stock			Paid-in		Subscription		Accumulated			Treasury Stock			controlling		Stockholders'
	Shares	Amount		Shares	Amount		Capital		Receivables		Deficit		Shares		Amount		Interest		Deficit
Balance as of January 1, 2023 (Predecessor)	21,257,708	$	137,949	138,848,177	$	14	$	187,348	$	—	$	(474,839)		(22,821)	$	(23)	$	17,087	$	(270,413)
Net loss	—		—	—		—		—		—		(60,678)		—		—		—		(60,678)
Stock-based compensation expense	—		—	—		—		—		—		—		—		—		3,235		3,235
Debt extinguishment due to warrant modification	—		—	—		—		17,036		—		—		—		—		—		17,036
Balance as of July 21, 2023 (Predecessor)	21,257,708	$	137,949	138,848,177	$	14	$	204,384	$	—	$	(535,517)		(22,821)	$	(23)	$	20,322	$	(310,820)


Balance as of July 22, 2023 (Successor) (As restated)	—	$	—	37,159,600	$	4	$	377,498	$	(60,710)	$	(149,648)		—	$	—	$	—	$	167,144
Net loss (as restated)	—		—	—		—		—		—		(323,954)		—		—		—		(323,954)
Stock-based compensation expense	—		—	—		—		3,766		—		—		—		—		—		3,766
Balance as of December 31, 2023 (Successor) (As restated)	—	$	—	37,159,600	$	4	$	381,264	$	(60,710)	$	(473,602)		—	$	—	$	—	$	(153,044)

Balance as of January 1, 2022 (Predecessor)	21,257,708	$	137,949	138,848,177	$	14	$	187,348	$	—	$	(422,283)		(22,821)	$	(23)	$	11,120	$	(223,824)
Net loss	—		—	—		—		—		—		(52,556)		—		—		—		(52,556)
Stock-based compensation expense	—		—	—		—		—		—		—		—		—		5,967		5,967
Balance as of December 31, 2022 (Predecessor)	21,257,708	$	137,949	138,848,177	$	14	$	187,348	$	—	$	(474,839)		(22,821)	$	(23)	$	17,087	$	(270,413)


Year ended December 31, 2022 (Predecessor)
Net loss available to common stockholders	$	(52,556)
Weighted average common shares outstanding, basic and diluted		138,848,177
Net loss per share attributable to common stockholders, basic and diluted	$	(0.38)


Period from January 1, 2023 to July 21, 2023 (Predecessor)
Net loss available to common stockholders	$	(60,678)
Weighted average common shares outstanding, basic and diluted		138,848,177
Net loss per share attributable to common stockholders, basic and diluted	$	(0.44)

Period from July 22, 2023 to December 31, 2023 (Successor) (As restated)
Net loss available to common stockholders (As restated)	$	(323,954)
Weighted average common shares outstanding, basic and diluted		37,159,600
Net loss per share attributable to common stockholders, basic and diluted (As restated)	$	(8.72)


Consolidated Statement of Operations and Comprehensive loss for the period from July 22, 2023 to December 31, 2023 (Successor)	As Reported		Adjustment		As Restated
Acquired in-process research and development	$	—	$	348,000	$	348,000
Total operating costs and expenses		(29,558)		348,000		318,442
Income (loss) from operations		29,558		(348,000)		(318,442)
Income (loss) before taxes		24,046		(348,000)		(323,954)
Net income (loss) and comprehensive income (loss)		24,046		(348,000)		(323,954)
Basic and diluted net income (loss) per share	$	0.65	$	(9.37)	$	(8.72)

Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit for the period from July 22, 2023 to December 31, 2023 (Successor)	As Reported		Adjustment		As Restated
Accumulated deficit, balance as of July 22, 2023 (Successor)	$	(180,856)	$	348,000	$	167,144
Net income (loss)	$	24,046	$	(348,000)	$	(323,954)


Condensed Consolidated Statement of Operations and Comprehensive loss for the period from July 22, 2023 to September 30, 2023 (Successor) (Unaudited)	As Reported		Adjustment		As Restated
Acquired in-process research and development	$	—	$	348,000	$	348,000
Total operating costs and expenses		(64,286)		348,000		283,714
Income (loss) from operations		64,286		(348,000)		(283,714)
Income (loss) before taxes		50,289		(348,000)		(297,711)
Net income (loss) and comprehensive income (loss)		50,289		(348,000)		(297,711)
Basic and diluted net income (loss) per share	$	1.35	$	(9.36)	$	(8.01)

Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit for the period from July 22, 2023 to September 30, 2023 (Successor) (Unaudited)	As Reported		Adjustment		As Restated
Accumulated deficit, balance as of July 22, 2023 (Successor)	$	(180,856)	$	348,000	$	167,144
Net income (loss)	$	50,289	$	(348,000)	$	(297,711)


Number of shares issued as consideration in the Merger		16,500,000
Shares issued for interim convertible notes related to Committed Financing		2,226,182
Total number of shares of common stock of the combined company		18,726,182
Multiplied by the Priveterra share price, as of the Closing	$	10.84
Total	$	202,992
Fair value of contingent consideration		125,699
Replacement of share-based payment awards		13,331
Assumed liabilities		125
Total purchase price	$	342,147


Cash and cash equivalents	$	2,001
Net working capital (excluding cash and cash equivalents)		(16,182)
Other assets and liabilities		775
Acquired in-process research and development		348,000
Net assets acquired		334,594
Loss on consolidation of VIE		7,553
Total purchase price	$	342,147


		Common shares		Common stock amount		Subscription Receivable		APIC		Accumulated Deficit
										(As restated)
Priveterra closing equity as of July 21, 2023		557,160	$	—	$	—	$	5,937	$	(12,897)
Shares issued as Consideration in the Merger	Note 1	16,500,000		2		—		192,189		—
Merger Consideration - Shares issued for Interim Convertible Notes related to Committed Financing	Note 7	2,226,182		—		—		24,132		—
Stock-Compensation for Class B Founder Shares	Note 5	6,900,000		1		—		68,972		(68,972)
Forward Purchase Agreements	Note 8	6,275,000		1		(60,710)		66,714		(38,255)
Issuance of Make-Whole derivative	Note 8	—		—		—		—		(427)
Shares issued in New Money PIPE Subscription Agreements	Note 8	1,001,000		—		—		10,844		(6,433)
Shares issued for Committed Financing	Note 8	3,571,429		—		—		38,714		(13,714)
Contingent Founder Shares	Note 8	—		—		—		(31,401)		—
Loss on Consolidation of VIE	Note 5	—		—		—		—		(7,553)
Other Miscellaneous		128,829		—		—		1,397		(1,397)
Total		37,159,600	$	4	$	(60,710)	$	377,498	$	(149,648)


		December 31,		July 21,
		2023		2023

Stock Price	$	7.20	$	10.84
Expected volatility		52.00%		55.00%
Risk-free interest rate		4.48%		4.82%
Expected life (in years)		1.56		2
Expected dividend yield		—		—


		Convertible Notes		Warrant Liabilities		Contingent Consideration		Embedded Forward Purchase Agreement and Make Whole Derivative
		(Level 3)		(Level 1)		(Level 3)		(Level 3)
Predecessor
Balance, December 31, 2022	$	131,292	$	-	$	-	$	-
Issuance of convertible notes		14,000		-		-		-
Change in fair value		19,359		-		-		-
Conversion to common shares		(164,651)		-		-		-
Balance, July 21, 2023		-		-		-		-


Successor
Balance, July 22, 2023		-		3,765		157,100		32,677
Additions		-		-		-		-
Change in fair value		-		(2,318)		(52,750)		8,366
Balance, December 31, 2023	$	-	$	1,447	$	104,350	$	41,043


Minimum lease payments by fiscal year
2024	$	292
Total future minimum lease payments		292
Less: Imputed interest		(14)
Present value of lease payments		278
Less: Current portion (included in other accrued expenses)		(278)
Noncurrent operating lease liability	$	—
Operating lease right-of-use asset	$	262
Remaining lease term in years		0.9
Discount rate		10	%


					Preferential		Carrying Value,
					Liquidation		Net of Issuance
	Shares	Shares Issued	Per Share		Value		Costs
	Authorized	and Outstanding	Preference		(in thousands)		(in thousands)
Series
Series A	7,393,333	2,505,508	$	5.4779	$	13,725	$	13,819
Series A-1	4,107,414	—		5.4779		—		—
Series A-2	4,846,750	4,846,750		5.4779		26,550		26,379
Series B	20,520,678	6,244,395		7.3097		45,645		43,896
Series B-1	136,805	—		7.3097		—		—
Series B-2	7,661,055	7,661,055		7.3097		56,000		53,855
	44,666,035	21,257,708			$	141,920	$	137,949


			Weighted
			Average
	Number of		Exercise
	Shares		Price
Predecessor
Outstanding, January 1, 2022	10,516,525	$	1.51
Options granted	—		—
Options forfeited	(821,635)		1.23
Outstanding, December 31, 2022	9,694,890		1.53
Exercisable, December 31, 2022	9,694,890	$	1.53

Outstanding, January 1, 2023	9,694,890	$	1.53
Options granted	—		—
Options forfeited	—		—
Options cancelled in connection with Merger	(9,694,890)		1.53
Outstanding, July 21, 2023	—		—
Exercisable, July 21, 2023	—	$	—


Exhibit No.		Description
2.1*		Business Combination Agreement, dated as of December 12, 2022, by and among Priveterra Acquisition Corp., Priveterra Merger Sub, Inc. and AEON Biopharma, Inc. (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Priveterra Acquisition Corp. with the SEC on December 13, 2022)
2.1(a)*		Amendment No. 1 to Business Combination Agreement, dated as of April 27, 2023, by and among Priveterra Acquisition Corp., AEON Biopharma, Inc. and Priveterra Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Priveterra Acquisition Corp. with the SEC on May 1, 2023)
3.1		Third Amended and Restated Certificate of Incorporation of AEON Biopharma, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Company with the SEC on July 27, 2023)
3.2		Amended and Restated Bylaws of AEON Biopharma, Inc. (incorporated by reference to Exhibit 3.2 to the Form 8-K filed by the Company with the SEC on July 27, 2023)
4.1		Warrant Agreement between Priveterra Acquisition Corp. and Continental Stock Transfer & Trust Company, dated as of February 8, 2021 (incorporated by reference to Exhibit 4.1 to the Form 10-K filed by Priveterra Acquisition Corp. with the SEC on March 28, 2022)
4.2		Specimen Warrant Certificate (incorporated by reference to Exhibit 4.1 to the Form 10-K filed by Priveterra Acquisition Corp. with the SEC on March 28, 2022)
4.3		Form of Senior Secured Convertible Note, by and among AEON Biopharma, Inc., Daewoong Pharmaceutical Co., LTD. and AEON Biopharma Sub, Inc. (incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Company with the SEC on March 19, 2024)
10.1+		Amended and Restated Employment Agreement, by and between AEON Biopharma, Inc. and Marc Forth (incorporated by reference to Exhibit 10.11 to the Form 8-K filed by the Company with the SEC on July 27, 2023)
10.2+		Employment Agreement, by and between AEON Biopharma, Inc. and Chad Oh (incorporated by reference to Exhibit 10.12 to the Form 8-K filed by the Company with the SEC on July 27, 2023)
10.3+		Employment Agreement, by and between AEON Biopharma, Inc. and Alex Wilson (incorporated by reference to Exhibit 10.13 to the Form 8-K filed by the Company with the SEC on July 27, 2023)
10.4+		Amended and Restated Registration Rights Agreement, dated as of July 21, 2023, by and between AEON Biopharma, Inc. and the stockholders party thereto (incorporated by reference to Exhibit 10.20 to the Form 8-K filed by the Company with the SEC on July 27, 2023)
10.5		Termination Agreement, dated March 18, 2024, by and between AEON Biopharma, Inc. and ACM ARRT J LLC (incorporated by reference to Exhibit 10.5 to the Form 8-K filed by the Company with the SEC on March 19, 2024)
10.6		Termination Agreement, dated March 18, 2024, by and between AEON Biopharma, Inc. and Polar Multi-Strategy Fund (incorporated by reference to Exhibit 10.6 to the Form 8-K filed by the Company with the SEC on March 19, 2024)
10.7		Subscription Agreement, dated March 19, 2024, by and between AEON Biopharma, Inc., Daewoong Pharmaceutical Co., LTD. and AEON Biopharma Sub, Inc. (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by the Company with the SEC on March 19, 2024)
10.8		Security Agreement, dated March 19, 2024, by and among AEON Biopharma, Inc., Daewoong Pharmaceutical Co., LTD. and AEON Biopharma Sub, Inc. (incorporated by reference to Exhibit 10.2 to the Form 8-K filed by the Company with the SEC on March 19, 2024)
10.9		Guaranty, dated March 19, 2024, by and between Daewoong Pharmaceutical Co., LTD. and AEON Biopharma Sub, Inc. (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by the Company with the SEC on March 19, 2024)
10.10		Fourth Amendment to License and Supply Agreement, dated March 19, 2024, by and between AEON Biopharma, Inc. and Daewoong Pharmaceutical Co., LTD. (incorporated by reference to Exhibit 10.4 to the Form 8-K filed by the Company with the SEC on March 19, 2024)
10.11		Consulting Agreement, by and between AEON Biopharma, Inc. and Eric Carter, M.D., dated January 30, 2020, and amended on January 30 2020 and September 30, 2020
23.1		Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
23.2		Consent of KPMG LLP, Independent Registered Public Accounting Firm.
31.1†		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2†		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1†		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2†		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
97†		AEON Biopharma, Inc. Policy for Recovery of Erroneously Awarded Compensation
101.INS†		XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH†		XBRL Taxonomy Extension Schema Document
101.CAL†		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF†		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB†		XBRL Taxonomy Extension Label Linkbase Document
101.PRE†		XBRL Taxonomy Extension Presentation Linkbase Document
104†		Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)


	AEON BIOPHARMA, INC.

	By:	/s/ Marc Forth
	Name:	Marc Forth
	Title:	President, Chief Executive Officer


Signature	Title	Date

/s/ Marc Forth	President, Chief Executive Officer and Director	May 14, 2024
Marc Forth	(Principal Executive Officer)

/s/ Peter Reynolds	Chief Financial Officer	May 14, 2024
Peter Reynolds	(Principal Financial Officer and Principal Accounting Officer)

/s/ Jost Fischer	Chairman of the Board	May 14, 2024
Jost Fischer

/s/ Eric Carter	Director	May 14, 2024
Eric Carter

/s/ Robert Palmisano	Director	May 14, 2024
Robert Palmisano

/s/ Seongsoo Park	Director	May 14, 2024
Seongsoo Park

/s/ Shelley Thunen	Director	May 14, 2024
Shelley Thunen


Date: May 14, 2024	/s/ Marc Forth
	Marc Forth
	President, Chief Executive Officer
	(Principal Executive Officer)

. JK
Date: May 14, 2024	/s/ Peter Reynolds
	Peter Reynolds
	Chief Financial Officer
	(Principal Financial Officer)


May 14, 2024			/s/ Marc Forth
			Marc Forth President, Chief Executive Officer (Principal Executive Officer)



May 14, 2024			/s/ Peter Reynolds
			Peter Reynolds Chief Financial Officer (Principal Financial Officer)